Evaluation of the pharmacokinetics and exposure-response relationship of dapagliflozin in patients without diabetes and with chronic kidney disease
Background and Objective Dapagliflozin, a sodium-glucose co-transporter inhibitor, was originally developed as an oral glucose-lowering drug for the treatment of type 2 diabetes mellitus. Emerging data suggest that cardiovascular and kidney benefits extend to patients without diabetes. Limited pharm...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Published: |
Adis
2021
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/34673/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|